In a phase II trial, the ROR1-targeting antibody–drug conjugate zilovertamab vedotin led to a complete response in nearly 100% of patients with diffuse large B-cell lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback